J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence,
Role: Investigator,
Eli Lilly & Co.,
(06/2024 - 06/2025)
Status: Approved
A Phase 3 Open-label, Randomized Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus
Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive
Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy
(TROPION-Breast03),
Role: Investigator,
AstraZeneca Pharmaceuticals, L.P. (USA),
(01/2024 - 01/2026)
Status: Approved
A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PII3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor,
Role: Investigator,
SynDevRx, Inc.,
(02/2025 - 02/2026)
Status: Approved
Internal
Investigator initiated CIPNGRASP: A pilot study of intraneural facilitation for managing chemotherapy-induced peripheral neuropathy,
Role: Investigator,
LLU Dept. of Medicine,
(04/2025 - 04/2026)
Status: Approved